Late Onset of Multiple Basal Cell Carcinomas in a Patient with Gorlin-Goltz Syndrome Previously Treated for Hodgkin’s Lymphoma/ Kasna pojava multiplog bazocelularnog karcinoma kod pacijenta sa Gorlin-Golcovim sindromom prethodno lečenog od Hočkinovog limfoma

Open access


Development of multiple basal cell carcinomas is commonly associated with immunosuppression or genetic disorders. The latter include congenital diseases such as Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome. It is an autosomal dominant inherited disorder characterized by the development of multiple basal cell carcinomas at an early age and a variable combination of other phenotypic abnormalities that result in multiple organ involvement. The susceptibility gene was mapped to chromosome 9q22.3-3.1. Like other tumor suppressor genes, PTCH1 gene shows frequent deletion and a whole variety of other mutations. A high rate of new mutations and the variable expressivity of the condition make full diagnostic assessment difficult, especially in mildly affected individuals with no family history of the condition. It has been postulated that the presence of two major features or one major feature with two minor features classify a condition as Gorlin-Goltz syndrome.

We present a 42-year-old male patient with a 6-year-long history of multiple smooth and/or rough skin patches and plaques on the back and shoulders. Some of the lesions gradually progressed and increased in number without any sensation. Dotlike, flesh-colored and brownish pits were found on the patient’s palms. Further investigations revealed many musculoskeletal and craniofacial congenital abnormalities such as pectus excavatum, frontal and parietal bossing, exotropia, ectopic teeth (impacted tooth), mandibular hyperplasia, broad nose. Histopathological examination by light microscopy of biopsies taken from the nodular and patchy skin lesions showed findings typical for basal cell carcinoma. Family history revealed no members with similar health disorders.

The patient was treated for Hodgkin’s lymphoma with chemotherapy and radiation therapy 20 years before, with good therapeutic results, and no additional treatment was administered in the last ten years.

The treatment for multiple basal cell carcinomas included: 5% imiquimod cream, 5 days a week, for 12 weeks. After 12 weeks of treatment, the nodular lesion and all the superficial lesions cleared. One month later the lesions disappeared completely without any residual signs.

The patient was advised to use adequate photoprotection and to avoid future uncontrolled sun exposure. On follow-up visits during a three year period, no recurrent or new lesions indicative for BCC were seen. This is a case with late-onset multiple BCC in a patient with Gorlin-Goltz syndrome and a history of prior Hodgkin’s lymphoma. To the best of our knowledge hitherto only two cases of Hodgkin’s lymphoma in patients with Gorlin-Goltz syndrome have been reported in the literature. We also present therapeutic results of topical imiquimod for multiple basal cell carcinomas with no recurrent lesions over a three-year follow-up.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Ferreres JR Macaya A Jucgla A Muniesa C Prats C Peyri J. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol. 2006;20:877-8.

  • 2. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanol J Rare Dis. 2008;3:32- 48.

  • 3. Roewert-Huber J Lange-Asschenfeldt B Stockfleth E Kerl H. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157(Suppl 2):47-51.

  • 4. Ortega Garcia de Amezaga A Garcia Arregui O Yepeda Nuno S Acha Sagredo A Aguirre Urizar JM. Gorlin-Goltz syndrome: clinicopathologic aspects. Med Oral Patol Oral Cir Bucal. 2008;13(6):E338-43.

  • 5. Dierks C. Small molecules in oncology: GDC-0449: targeting the hedgehog signaling pathway. Recent Results in Cancer Res. 2010;184:235-8.

  • 6. Bree AF Shah MR BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet. 2011;155A (9):2091-7.

  • 7. Kimonis VE Goldstein AM Pastakia B Yang ML Kase R DiGiovanna JJ et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299-308.

  • 8. Evans DG Ladusans EJ Rimmer S Burnell LD Thakker N Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460-4.

  • 9. Jones EA Sajid MI Shenton A Evans DG. Basal cell carcinomas in Gorlin syndrome: a review of 202 patients. J Skin Cancer. 2011;2011:217378.

  • 10. Kimonis VE Singh KE Zhong R Pastakia B Digiovanna JJ Bale SJ. Clinical and radiological features in young individuals with nevoid basal cell carcinoma syndrome. Genet Med. 2013;15:79-83.

  • 11. Gorlin RJ Goltz RW. Multiple nevoid basal-cell epithelioma jaw cysts and bifid rib: a syndrome. N Engl J Med. 1960;262:908-12.

  • 12. Jarisch W. Zur Lehre von den Hautgeschwulsten. Arch Dermatol Syphilol. 1894;28:162-222.

  • 13. White JC. Multiple benign cystic epitheliomas. J Cutan Genitourin Dis. 1894;12:477-84.

  • 14. Binkley GW Johnson HH. Epithelioma adenoides cysticum: basal cell nevi agenesis of the corpus callosum and dental cysts: a clinical and autopsy study. AMA Arch Dermatol Syphiol. 1951;63:73-84.

  • 15. Gorlin RJ Yunis JJ Tuna N. Multiple nevoid basal cell carcinoma odontogenic keratocysts and skeletal anomalies: a syndrome. Acta Derm Venereol. 1963;43:39-55.

  • 16. Gorlin RJ Vickers RA Kelln E Williamson JJ. Multiple basal cell nevi syndrome. An analysis of a syndrome consisting of multiple nevoid basal-cell carcinoma jaw cysts skeletal anomalies medulloblastoma and hyporesponsiveness to parathormone. Cancer 1965;18:89-104.

  • 17. Jawa DS Sircar K Somani R Grover N Jaidka S Singh S. Gorlin-Goltz syndrome. J Oral Maxillofac Pathol. 2009;13:89-92.

  • 18. Patil KV Mahima G Gupta B. Gorlin syndrome: a case report. J Indian Soc Pedod Prev Dent. 2005;23:198-203.

  • 19. Shivaswamy KN Sumathy TK Shyamprasad AL Ranganathan C. Gorlin syndrome or basal cell nevus syndrome (BCNS): a case report. Dermatol Online J. 2010;16(9):6.

  • 20. Kohli M Kohli M Sharma N Siddiqui SR Tulsi SP. Gorlin- Goltz syndrome. Natl J Maxillofac Surg. 2010;1(1):50-2.

  • 21. Blackburn EH. Cancer interception. Cancer Prev Res (Phila). 2011;4:787-92.

  • 22. Casaroto AR Loures DC Moreschi E Veltrini VC Trento CL Gottardo VD et al. Early diagnosis of Gorlin-Goltz syndrome: case report. Head Face Med. 2011;7:2.

  • 23. Leonardi R Santarelli A Barbato E Ciavarella D Bolouri S Harle F et al. Atlanto-occipital ligament calcification: a novel sign in nevoid basal cell carcinoma syndrome. Anticancer Res. 2010;30(10):4265-7.

  • 24. Pinto LSS Carlos-Bregni R Junior HM Filho MRM Azanero WD Leon JE et al. Nevoid basal cell carcinoma syndrome: an analysis of four familial and two sporadic cases. J Oral Diag. 2012;1(1):20-5.

  • 25. Yordanova I Gospodinov D Kirov V Pavlova V Radoslavova G. A familial case of Gorlin-Goltz syndrome. J IMAB - Ann Proceed (Scient Papers). 2007;13(1):63-7.

  • 26. Potaznik D Steinherz P. Multiple nevoid basal cell carcinoma syndrome and Hodgkin’s disease. Cancer. 1984;53(12):2713-5.

  • 27. Zvulunov A Strother D Zirbel G Rabinowitz LG Esterly NB. Nevoid basal cell carcinoma syndrome. Report of a case with associated Hodgkin’s disease. J Pediatr Hematol Oncol. 1995;17(1):66-70.

  • 28. Penel N Robin YM Mallet Y Gauthier H Vanseymortier L. Association head and neck angiosarcoma and nevoid basal cell carcinoma syndrome (Gorlin syndrome). Oral Oncol Extra. 2005;41:289-91.

  • 29. Pereira CM Lopes AM Meneghini AJ Silva AF Botelho TdeL. Oral diffuse B-cell non-Hodgkin’s lymphoma associated to Gorlin-Goltz syndrome: a case report with one year followup. Indian J Pathol Microbiol. 2011;54:388-90.

  • 30. Schulz-Butulis BA Gilson R Farley M Keeling JH. Nevoid basal cell carcinoma syndrome and non-Hodgkin’s lymphoma. Cutis. 2000;66:35-8.

  • 31. Mitropoulos P Norman R. Nevoid basal cell carcinoma syndrome (Gorlin syndrome): updated review of minimally invasive treatments. Cutis. 2008;81:53-60.

  • 32. Neville JA Williford PM Jorizzo JL. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. J Drugs Dermatol. 2007;6(9):910-4.

  • 33. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32(1):63-9.

  • 34. Torres A Niemeyer A Berkes B Marra D Schanbacher C Gonzalez S et al. 5% imiquimod cream and reflectancemode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Dermatol Surg. 2004;30(12 Pt 1):1462-9.

  • 35. Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013;10(6):651-65.

  • 36. Beach DF Somer R. Novel approach to Gorlin syndrome: a patient treated with oral capecitabine. J Clin Oncol. 2011;29(14):e397-401.

  • 37. Love WE Bernhard JD Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma. A systematic review. Arch Dermatol. 2009;145(12):1431-8.

  • 38. Thissen MR Kuijpers DI Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5(5):461-4.

  • 39. Doctoroff A Oberlender SA Purcell SM. Full-face carbon dioxide laser resurfacing in the management of a patient with the nevoid basal cell carcinoma syndrome. Dermatol Surg. 2003;29(12):1236-40.

  • 40. Alessi SS Sanches JA Oliveira WR Messina MC Pimentel ER Festa Neto C. Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream. Clinics (Sao Paulo). 2009;64(10):961-6.

  • 41. Kagy MK Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 2000;26(6):577-9.

  • 42. Micali G Lacarrubba F Nasca MR De Pasquale R. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003;28 (Suppl 1):19-23.

  • 43. Micali G De Pasquale R Caltabiano R Impallomeni R Lacarrubba F. Topical imiquimod treatment of superficial and nodular basal cell carcinomas in patients affected by basal cell nevus syndrome: a preliminary report. J Dermatol Treat. 2002;13(3):123-7.

  • 44. Vereecken P Monsieur E Petein M Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat. 2004;15(2):120-1.

  • 45. Amon RB Goodkin PE. Topical 5-fluorouracil and the basalcell- nevus syndrome. N Engl J Med. 1976;295(12):677-8.

  • 46. Strange PR Lang PG Jr. Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. J Am Acad Dermatol. 1992;27(5 Pt 2):842-5.

  • 47. Van Ruth S Jansman FG Sanders CJ. Total body topical 5-fluorouracil for extensive non-melanoma skin cancer. Pharm World Sci. 2006;28(3):159-62.

  • 48. Cristofolini M Zumiani G Scappini P Piscioli F. Aromatic retinoid in the chemoprevention of the progression of nevoid basal-cell carcinoma syndrome. J Dermatol Surg Oncol. 1984;10(10):778-81.

  • 49. Goldberg LH Hsu SH Alcalay J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J Am Acad Dermatol. 1989;21(1):144-5.

  • 50. Lien MH Sondak VK. Nonsurgical treatment options for basal cell carcinoma. J Skin Cancer. 2011; 2011: 571734.

  • 51. Shumack S Rigel D. Treatment of non-melanoma skin cancer: immunotherapy. Acta Derm Venereol Suppl. 2003;214:18-22.

  • 52. Stockfleth E Ulrich C Hauschild A Lischner S Meyer T Christophers E. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569-72.

  • 53. Tillman DK. Carroll MT. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol. 2008;7(Suppl 1):s7-14.

  • 54. Tillman DK Jr Carroll MT. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience. Cutis. 2007;79(3):241-8.

  • 55. Wu JK Oh C Strutton G Siller G. An open-label pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006;47(1):46-8.

  • 56. Geisse J Caro I Lindholm J Golitz L Stampone P Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III randomized vehiclecontrolled studies.J Am Acad Dermatol. 2004;50(5):722-33.

  • 57. Slade HB Owens ML Tomai M Miller RL. Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs. 1998;7(3):437-49.

  • 58. Suzuki H Wang B Shivji GM Toto P Amerio P Tomai MA et al. Imiquimod a topical immune response modifier induces migration of Langerhans cells. J Invest Dermatol. 2000;114(1):135-41.

  • 59. Cozzi SJ Le TT Ogbourne SM James C Suhrbier A. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res. 2013;305(1):79-83.

  • 60. Wood ME Vogel V Ng A Foxhall L Goodwin P Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30(30):3734-45.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 310 96 1
PDF Downloads 134 56 2